Af­ter spurn­ing Sanofi for di­a­betes dis­ap­point­ment, Zealand nets FDA ap­proval in se­vere hy­po­glycemia

About two and a half years af­ter sell­ing off roy­al­ties on a dis­ap­point­ing Sanofi-part­nered di­a­betes drug, Zealand Phar­ma now has its own in-house pro­gram to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.